These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Differential regulation of smooth muscle markers in human bone marrow-derived mesenchymal stem cells. Hegner B; Weber M; Dragun D; Schulze-Lohoff E J Hypertens; 2005 Jun; 23(6):1191-202. PubMed ID: 15894895 [TBL] [Abstract][Full Text] [Related]
23. Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex 1 and FoxO4. Ding M; Xie Y; Wagner RJ; Jin Y; Carrao AC; Liu LS; Guzman AK; Powell RJ; Hwa J; Rzucidlo EM; Martin KA Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1403-10. PubMed ID: 21454807 [TBL] [Abstract][Full Text] [Related]
24. Thrombin induces expression of FGF-2 via activation of PI3K-Akt-Fra-1 signaling axis leading to DNA synthesis and motility in vascular smooth muscle cells. Cao H; Dronadula N; Rao GN Am J Physiol Cell Physiol; 2006 Jan; 290(1):C172-82. PubMed ID: 16148030 [TBL] [Abstract][Full Text] [Related]
25. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609 [TBL] [Abstract][Full Text] [Related]
26. Negative regulation of melanogenesis by phospholipase D1 through mTOR/p70 S6 kinase 1 signaling in mouse B16 melanoma cells. Ohguchi K; Banno Y; Nakagawa Y; Akao Y; Nozawa Y J Cell Physiol; 2005 Dec; 205(3):444-51. PubMed ID: 15895362 [TBL] [Abstract][Full Text] [Related]
27. Interferon-gamma and intimal hyperplasia. Rose ML Circ Res; 2007 Sep; 101(6):542-4. PubMed ID: 17872472 [No Abstract] [Full Text] [Related]
28. Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation. Lee SJ; Yang EK; Kim SG Mol Pharmacol; 2006 Jul; 70(1):415-25. PubMed ID: 16611854 [TBL] [Abstract][Full Text] [Related]
29. Effect of sirolimus on arteriosclerosis induced by advanced glycation end products via inhibition of the ILK/mTOR pathway in kidney transplantation recipients. Xu Z; Liu X; Wang Z; Tao J; Han Z; Gu M; Zhang W; Tan R Eur J Pharmacol; 2017 Oct; 813():1-9. PubMed ID: 28669853 [TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease. Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435 [TBL] [Abstract][Full Text] [Related]
31. S6K Promotes Dopaminergic Neuronal Differentiation Through PI3K/Akt/mTOR-Dependent Signaling Pathways in Human Neural Stem Cells. Lee JE; Lim MS; Park JH; Park CH; Koh HC Mol Neurobiol; 2016 Aug; 53(6):3771-3782. PubMed ID: 26143260 [TBL] [Abstract][Full Text] [Related]
32. The immunosuppressant tributyltin oxide blocks the mTOR pathway, like rapamycin, albeit by a different mechanism. Osman AM; van Loveren H J Appl Toxicol; 2014 Dec; 34(12):1361-7. PubMed ID: 24375594 [TBL] [Abstract][Full Text] [Related]
33. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Cao X; Kambe F; Moeller LC; Refetoff S; Seo H Mol Endocrinol; 2005 Jan; 19(1):102-12. PubMed ID: 15388791 [TBL] [Abstract][Full Text] [Related]
34. Development of a sensitive phospho-p70 S6 kinase ELISA to quantify mTOR proliferation signal inhibition. Hartmann B; He X; Keller F; Fischereder M; Guba M; Schmid H Ther Drug Monit; 2013 Apr; 35(2):233-9. PubMed ID: 23503450 [TBL] [Abstract][Full Text] [Related]
35. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Khamzina L; Veilleux A; Bergeron S; Marette A Endocrinology; 2005 Mar; 146(3):1473-81. PubMed ID: 15604215 [TBL] [Abstract][Full Text] [Related]
36. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128 [TBL] [Abstract][Full Text] [Related]